BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions

Reuters

06 Mar

BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions

March 5 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:

ARS PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF NEFFY® 1 MG (EPINEPHRINE NASAL SPRAY) FOR TYPE I ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, IN PEDIATRIC PATIENTS WEIGHING 15 TO < 30 KILOGRAMS
ARS PHARMACEUTICALS INC - NEFFY 1 MG IS EXPECTED TO BE AVAILABLE IN U.S. BY END OF MAY 2025
ARS PHARMACEUTICALS: MOST COMMERCIALLY INSURED PATIENTS WILL PAY NO MORE THAN $25 FOR TWO SINGLE-USE NEFFY DEVICES THROUGH A CO-PAY SAVINGS PROGRAM
ARS PHARMACEUTICALS INC: IF PRODUCT ISN'T COVERED BY INSURANCE, CASH PRICE OF $199 FOR TWO DOSES IS AVAILABLE THROUGH BLINKRX

Source text: ID:nGNX3b0hhs

Further company coverage: SPRY.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/news/2517927311"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517927311\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2517927311?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-06 06:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517927311","market":"nz","top_or_hot":-1,"title":"BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions</title></head><body><p><span>March 5 (Reuters)</span><span> - </span>ARS Pharmaceuticals Inc <span>SPRY.O</span>:</p><ul><li><p>ARS PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF NEFFY® 1 MG (EPINEPHRINE NASAL SPRAY) FOR TYPE I ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, IN PEDIATRIC PATIENTS WEIGHING 15 TO &lt; 30 KILOGRAMS</p></li><li><p><a href=\"https://laohu8.com/S/SPRY\">ARS PHARMACEUTICALS INC</a> - NEFFY 1 MG IS EXPECTED TO BE AVAILABLE IN U.S. BY END OF MAY 2025</p></li><li><p>ARS PHARMACEUTICALS: MOST COMMERCIALLY INSURED PATIENTS WILL PAY NO MORE THAN $25 FOR TWO SINGLE-USE NEFFY DEVICES THROUGH A CO-PAY SAVINGS PROGRAM</p></li><li><p>ARS PHARMACEUTICALS INC:  IF PRODUCT ISN'T COVERED BY INSURANCE, CASH PRICE OF $199 FOR TWO DOSES IS AVAILABLE THROUGH BLINKRX</p></li></ul><p>Source text: <span>ID:nGNX3b0hhs</span></p><p>Further company coverage: <span>SPRY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-06 06:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions</title></head><body><p><span>March 5 (Reuters)</span><span> - </span>ARS Pharmaceuticals Inc <span>SPRY.O</span>:</p><ul><li><p>ARS PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF NEFFY® 1 MG (EPINEPHRINE NASAL SPRAY) FOR TYPE I ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, IN PEDIATRIC PATIENTS WEIGHING 15 TO &lt; 30 KILOGRAMS</p></li><li><p><a href=\"https://laohu8.com/S/SPRY\">ARS PHARMACEUTICALS INC</a> - NEFFY 1 MG IS EXPECTED TO BE AVAILABLE IN U.S. BY END OF MAY 2025</p></li><li><p>ARS PHARMACEUTICALS: MOST COMMERCIALLY INSURED PATIENTS WILL PAY NO MORE THAN $25 FOR TWO SINGLE-USE NEFFY DEVICES THROUGH A CO-PAY SAVINGS PROGRAM</p></li><li><p>ARS PHARMACEUTICALS INC:  IF PRODUCT ISN'T COVERED BY INSURANCE, CASH PRICE OF $199 FOR TWO DOSES IS AVAILABLE THROUGH BLINKRX</p></li></ul><p>Source text: <span>ID:nGNX3b0hhs</span></p><p>Further company coverage: <span>SPRY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nTUA4R29QJ:1","article_id":"2517927311","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517927311","pubTimestamp":1741212595,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy 1 mg (epinephrine nasal spray) for Type I Allergic ReactionsMarch 5 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS ANNOUNCES F","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简报-ARS Pharmaceuticals宣布FDA批准奈菲®1 mg（肾上腺素鼻喷雾剂）治疗I型过敏反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":0.9},"content_text":"BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic ReactionsMarch 5 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF NEFFY® 1 MG (EPINEPHRINE NASAL SPRAY) FOR TYPE I ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, IN PEDIATRIC PATIENTS WEIGHING 15 TO < 30 KILOGRAMSARS PHARMACEUTICALS INC - NEFFY 1 MG IS EXPECTED TO BE AVAILABLE IN U.S. BY END OF MAY 2025ARS PHARMACEUTICALS: MOST COMMERCIALLY INSURED PATIENTS WILL PAY NO MORE THAN $25 FOR TWO SINGLE-USE NEFFY DEVICES THROUGH A CO-PAY SAVINGS PROGRAMARS PHARMACEUTICALS INC:  IF PRODUCT ISN'T COVERED BY INSURANCE, CASH PRICE OF $199 FOR TWO DOSES IS AVAILABLE THROUGH BLINKRXSource text: ID:nGNX3b0hhsFurther company coverage: SPRY.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}